Menin inhibitors represent a novel targeted therapy class developed for these specific AML subsets with MLL rearrangements or NPM1 mutations, which constitutes a significant portion of AML patients with normal karyotypes [63]. Here, NPM1 is linked to acute myeloid leukemia.